Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical

Vandana Singh
1 min read
0
In this article:

  • Fusion Pharmaceuticals Inc (NASDAQ: FUSN) acquired the investigational new drug application for an ongoing Phase 2 TATCIST trial evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancers, from RadioMedix Inc.

  • Following the closing, the alpha-emitting radiopharmaceutical evaluated in the TATCIST trial will be known as FPI-2265.

  • The TATCIST trial is evaluating metastatic castration-resistant prostate cancer patients with progressive disease, including patients who are naïve to PSMA-targeted radiopharmaceuticals and those who have been pre-treated with 177Lu-based PSMA radiopharmaceutical.

  • The trial is expected to evaluate approximately 100 patients, with four treatment cycles per patient occurring every eight weeks. Patients are initially dosed at 100 kBq/kg, with dose de-escalation possible based on biochemical response.

  • Efficacy will be assessed using changes in PSA levels and radiographic response.

  • Fusion plans to expand the Phase 2 program to additional sites and expects to report data on 20 to 30 patients in Q1 of 2024.

  • In connection with the closing of the acquisition of the TATCIST trial and related assets, Fusion has announced a private placement of $60 million.

  • Fusion will issue approximately 17.6 million shares at $3.40/share.

  • The company anticipates a cash balance of $248.0 million, sufficient to fund its planned operating expenses and capital expenditure requirements into Q1 of 2025.

  • Price Action: FUSN shares are up 30.70% at $4.73 during the premarket session on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories